Boston, MA 02/10/2014 (wallstreetpr) – Galena Biopharma Inc (NASDAQ:GALE): Investor confidence returned in GALE, enabling the company to close Friday’s session 15.46 percent above the previous closing. The stock had tumbled nearly 5 percent when it missed to issue yearly guidance Sovaldi, its new hepatitis C drug. Analysts and investors had hoped the company would issue projection of the expected revenue from the drug, but that was not to happen, and the stock plummeted. However, having had time to digest the news and perhaps coming to understand that Sovaldi has the potential of boosting the stock price in the long run even if a rival drug being fronted by AbbVie succeeds, investor confidence in Galena Biopharma Inc (NASDAQ:GALE) soared last Friday.
Xerox Corporation (NYSE:XRX) is about to change the way doctors and patients undergo some disease monitoring. The solution will be particularly useful in cases of cardiovascular and respiratory conditions which require difficult, continuous and in most case, expensive monitoring. The research for this upcoming solution is being undertaken by Xerox Research Center Webster and Xerox Research Center India. Also involved in the study is the Manipal University Hospital, India. The technology will feature data analytics and video cameras that can monitor patients’ condition without contact, thus making disease monitor comfortable and devoid of infection risks. In all these, Xerox Corporation (NYSE:XRX) is proving to be a worthy player in combining bio and tech to deliver the solutions that people need.
Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) has refused to break under $10 per share. The stock managed a rare lift Friday, touching $11.09 – $11.46 during the day before settling at $11.34, suggesting more than 1 percent gain. Most everyone knows that the company has remained in a troubled position of the past year. And the shares are down more than 21 percent in 2014. Yet, we can see that no analysts rate the stock a “sell.” Instead, Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) carried a “buy” tag from three analysts and a “hold” tag from six analysts.
